CAMBRIDGE, Mass. - Moderna announced Thursday that it has asked the U.S. Food and Drug Administration to expand the emergency approval of its COVID-19 vaccine to those aged 12 to 17.
The company said it was encouraged by data from its ongoing trial that found the two-dose vaccine was both safe and effective in adolescents.
If Moderna’s emergency use authorization is expanded to include the younger age group, it would dramatically increase the number of shots available to students ahead of the next school year.